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LONGITUDINAL EVALUATION IN PATIENTS WITH RHEUMATOID
ARTHRITIS
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* Department of Rheumatology, t Department of Internal Medicine, \Department of Medical Statistics,
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SUMMARY
In a recent study from our group, the combination of methotrexate and sulphasalazine (MTX + SASP) seemed superior to MTX 
alone in the treatment of rheumatoid arthritis (RA). To assess the impact of these therapies on the cytokine cascade, the in vitro 
production and circulating concentrations of several cytokines and endogenous cytokine antagonists were measured in 30 healthy 
controls and longitudinally in a subset of 26 patients enrolled in this study. Compared to controls, RA patients had significantly 
higher circulating concentrations of interleukin-6 (IL-6), soluble receptors for tumour necrosis factor (sTNFR), soluble receptors 
for interleukin-2 (sIL-2R) and interleukin-1 receptor antagonists (IL-1RA), and their peripheral blood mononuclear cells 
(PBMNC) showed a higher spontaneous production of interleukin-1/i (IL-l/i), tumour necrosis factor a (TNFa) and IL-1RA 
(both secreted and cell-associated) and a higher stimulated production of cell-associated TNFa, IL-1RA and (to a lesser extent) 
IL-l/i. Treatment with MTX alone (n = 12) or combined with SASP (n = 14), resulted in significant reductions of circulating 
IL -6 and sIL-2R but did not alter IL-l/i, TNFa or IL-1RA concentrations. Decreases in circulating levels of sTNFR and in 
the in vitro production of cell-associated IL-l/i and IL-1RA after stimulation were only observed in patients treated with 
MTX + SASP. The concentrations of IL-1RA and sTNFR in the circulation exceeded moderately those of IL-l/i and TNFa 
but this is probably insufficient to block IL-1 and TNFa activity. In conclusion, therapy with MTX alone or with SASP modulates 
IL -6 and sIL-2R concentrations in RA. Decreased production of IL-l/i and IL-1RA and circulating sTNFR levels were only 
observed during therapy with MTX -f SASP. Whether this relates to the better clinical effect observed with the combination 
therapy remains to be investigated. Circulating levels of IL-6, sIL-2R and sTNFR seem useful markers of disease activity in 
RA.
K ey  w o r d s : Cytokines, Methotrexate, Sulphasalazine, Combination therapy.
The involvement of cytokine networks in the pathogen­
esis of rheumatoid arthritis (RA) is proved beyond 
discussion [1,2]. Proinflammatory cytokines such 
as interleukin-1 (IL-1) and tumour necrosis factor a 
(TNFa) [3,4] are present in the rheumatoid synovial 
membrane and implicated in cell proliferation, syn­
thesis of prostaglandins, metalloproteinases and inter- 
leukin-6 (IL-6) [5], proteoglycan breakdown and bone 
resorption [1]. Intra-articular injection of IL-1 [6] and 
TNF [7] result in joint inflammation and blocking IL-1 
and TNF ameliorates several animal models of arthritis 
[8, 9]. IL-6, the major inducer of acute-phase response 
[10], is also present in RA synovial tissue [2] and 
may amplify the inflammatory process by its action on 
B- and T-cells [1]. However, in contrast to IL-1 and 
TNF, IL-6 does not enhance prostaglandins or col- 
lagenase production and may counteract inflammation 
by enhancing the synthesis of tissue inhibitor of metal- 
loproteinase-1 [11] and reducing IL-1 and TNF pro-
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duction [12]. The role of these cytokines in human
t
arthritis is supported by preliminary studies showing 
improvement during IL-1 [13], TNF [14], and IL-6 [15] 
blockade in RA patients.
The activity of cytokines in biological fluids is subject 
to modulation by natural inhibitors and soluble 
cytokine receptors. The IL-1 receptor antagonist (IL- 
1RA), a competitive inhibitor of IL-1 which binds 
to the IL-1 receptors without inducing a biological 
response [16] is present in the rheumatoid synovial 
membrane [17]. High concentrations of soluble recep­
tors for IL-2 (sIL-2R) [18-20] and TNF (sTNFR) 
[19, 21] have been detected in plasma and synovial fluid 
of RA patients. The sIL-2R, a soluble form of the 
a chain IL-2 receptor, is a marker of lymphocyte 
activation in vivo [22] and may be useful to monitor 
disease activity in RA [18]. The two types of sTNFR 
(p55 and p75) are shed from the cellular membrane 
and bind to TNF in solution acting as endogenous 
TNF antagonists [23].
Methotrexate (MTX) and sulphasalazine (SASP) are 
currently used anti-rheumatic drugs. Although their 
mechanism of action remains unclear, several reports 
suggest that these drugs may differ in their effects on 
circulating cytokines and cytokine production. In vitro 
studies with MTX have shown inhibitory effects on
(c) 1995 British Society for Rheumatology
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IL-1 [24] and IL-6 but not TNF bioactivity [25] while 
SASP has been reported to decrease IL-1 [26,27] and 
TNF [27] production and to inhibit the binding of 
TNFa to its receptor [28]. Furthermore in RA patients, 
decreases in synovial levels of IL-1 fi [29], in the pro­
duction of IL-1 by peripheral blood mononuclear cells 
(PBMNC) [30, 31] and in circulating concentrations of 
IL-6, p55 sTNFR [19] and sIL-2R [19,20] have been 
reported during MTX, whereas treatment with SASP 
has been associated with reductions in IL-1 a, IL-l/i and 
TNFa [32], but not in sIL-2R [33] or IL-6 [32] concen­
trations, though the latter was not corroborated in 
another study [34].
To date, the effect of combination therapy with 
MTX and SASP on cytokines has not been assessed. 
Therefore, after a recent study in our centre showed 
that the combination of MTX and SASP was superior 
to MTX alone in the treatment of active RA [35], we 
analysed the effects of these therapies on circulating 
levels and on the in vitro production of several 
cytokines and their endogenous antagonists.
PATIENTS
Twenty-six patients with active RA enrolled in a 
24-week, randomized, open trial of MTX vs MTX in 
combination with SASP [35] and 30 healthy controls 
(laboratory staff) were studied. Cytokine concen­
trations were assessed at baseline and after 4, 8 and 24 
weeks. Fourteen additional patients enrolled in the 
original clinical study [35] were excluded from cytokine 
measurements since they were controlled in another 
centre. Active RA was defined as a disease activity 
score (DAS) >3. The DAS is a validated score 
composed of the Ritchie Articular Index, number of 
swollen joints, erythrocyte sedimentation rate (ESR) 
and patient well-being on a visual analogue scale [36]. 
Twelve patients were allocated to therapy with MTX 
alone (7.5 mg weekly in a single dose) and 14 patients 
to the combination MTX + SASP (2000 mg daily in 
two doses). If no clinical improvement was observed 
after 16 weeks, the MTX dose was increased to 
15 mg weekly. Non-steroidal anti-inflammatory drugs 
(NSAIDs) were kept at a stable dose and no cortico­
steroids were administered either at study entry or 
during the study.
METHODS
Circulating cytokine concentrations
Blood samples used to assess circulating cytokines 
(IL-l/i, TNFa, IL-1 RA) and soluble receptors (sIL-2R, 
sTNFR) were drawn in Vacutainer tubes (Becton & 
Dickinson, Rutherford, NJ, USA), containing 48/d 
EDTA-K3and 250 fi\ aprotinin (10 000 kallikrein inac­
tivating units/ml, Bayer, Mijdrecht, The Netherlands). 
IL-6 was measured in serum from a Vacutainer tube 
without additives. Samples were centrifuged lOmin at 
2250 g and 5 min at 15 000g to remove the platelets 
and frozen at — 80 C until assay.
Cytokine production by PBMNC
The production of IL-l/f, TNFa and IL-1RA was 
assessed. sTNFR production was not measured since 
PBMNC do not seem to release these receptors either 
spontaneously or after LPS stimulation [31]. PBMNC 
were isolated from heparinized blood by Percoll 
(Pharmacia, Upsala, Sweden) centrifugation 
((} = 1.075 g/ml) at 4 C and washed twice in saline. 
PBMNC were suspended at a concentration of 5 x 106 
cells/ml in RPMI complete medium [RPMI 1640 
medium with 20 mM HEPES (Flow, UK) supplemented 
with 2 mM L-glutamine (Gibco, New York, USA), 
1 mM pyruvic acid (Sigma, St Louis, MO, USA), 
50//g/ml gentamicin and 5% heat-inactivated pooled 
human serum]. Aliquots of 100//I (5 x 10" cells) were 
added to 96-well round-bottomed microtitre plates 
(Greiner, Feirickenhausen, Germany). An equal vol­
ume of RPMI complete medium with or without 
lipopolisaccharide (LPS) (50 ng/ml final concentration) 
was added. The plates were incubated at 37 C in a 
humidified, 5% CO: atmosphere for 24 h. Thereafter, 
the supernatants containing secreted cytokines, were 
centrifuged for 5 min at 13 000g. The remaining cell 
fractions were resuspended in 200//I RPMI complete 
medium/well and exposed to three freeze-thaw cycles 
to lyse the cells and obtain material to measure cell- 
associated cytokines. The samples were stored at
— 80 C. The RPMI culture medium, Percoll and saline 
used in this study were sterile and pyrogen-free.
Cytokine assays
IL-1 /j, TNFa [31] and IL-1RA [37] were assessed by 
radioimmunoassays (RIA) with an average sensitivity 
of 40, 60 and 150pg/ml, respectively. The RIAs for 
IL-l/i and IL-1RA are specific, i.e. the coexistence of 
IL-l/i and IL-1RA in a given sample does not alter the 
results (unpublished results and [37]). IL-6 was 
measured by a B9 hybridoma bioassay with a sensi­
tivity of 0.3 U/ml. As previously reported, this assay is 
not influenced by treatment with MTX or SASP [38]. 
sTNFR (p55 and p75) were measured by enzyme- 
linked binding assay (ELIBA) (kind gift of Dr H. 
Gallati, Hoffmann la Roche, Basel, Switzerland) with 
a sensitivity of 100pg/ml. The assays for TNFa 
and sTNFR measure total concentrations (both free 
levels and complexes of TNF and sTNFR) as pre­
viously reported [31]. sIL-2R was measured using 
an enzyme-linked immunosorbent assay (ELISA) 
(Innotest hIL-2Rs, Innogenetics, Antwerp, Belgium), 
according to the manufacturer’s instructions. The aver­
age sensitivity of this ELISA is 390 pg/ml. To minimize 
interassay variations, all samples were measured in a 
single assay.
STATISTICAL ANALYSIS
Baseline variables were compared using the Student 
/-test or Wilcoxon rank sum test. Closed testing pro­
cedures [39] were used to compare cytokine measure­
ments during the study with pretreatment values. 
Differences in cytokine concentrations between groups 
during the 24-week follow-up were analysed by a
TABLE I
Clinical and laboratory parameters at baseline (mean±s.D.), and changes after 24 weeks of treatment (mean and 95% confidence intervals)
Baseline Changes week 24 vs baseline
Variable M TX {n = 12) M TX + SASP (/; =  14) M TX M TX + SASP P
Age (yr) 52.2 ± 13.6 58.9 ± 10.6
Sex (female/male) 9/3 12/2
Disease duration (yr) 4.9 ±4.8 4.6 ± 4.6
Previous D M A R D s  (number) 0.75 ± 1.16 0.79 ± 1.01
Duration SASP use (months) 23.9 ± 14.3 20.1 ± 13.8
RF  positive (number) 10 11
Ritchie articular index 16.6 ±5.3 18.4 ± 7.1 7.4 (-11 to -3.8) -15.4 ( — 18.5 to -12.2) <0.005
DAS 5.1 ±0.6 5.3 ±0.9 -1.1 ( — 1.8 to -0.5) -2.8 ( — 3.3 to -2.4) <0.001
Number swollen joints 23.7 ±6.7 22.3 ±7.1 -3.8 ( — 6.2 to -1.3) -13.5 ( — 17.5 to -9.5) <0.001
Number painful joints 21.9 ±8.2 26.2 ±6.2* -10.3 ( — 15.1 to -5.4) -22.6 ( — 25.8 to 19.4) <0.001
VAS wellbeing (mm) 43.4 ± 14.9 60.4 ± 25.4 -9.2 (-25.1 to 6.8) -33.5 ( — 46.6 to -20.4) <0.05
VAS pain (mm) 49.9 ± 19.0 61.0 ± 19.5 -16.9 (-31.9 to -1.9) -39.2 ( — 50.4 to -28) <0.05
Morning stiffness (min) 107 ±93 101 ±89 -30 (-  105 to 45) -88 (-131 to -46)
Grip strength right/left hand (kPa) 19.1/17.8 ± 10.5/9.5 22.4/18.4 ± 19.8/10.4 6.0/6.6 (0.6 to 11.4/0 to 13.1) 14.2/17.9 (9.3 to 19.2/9 .2 to 26.7) <0.05
ESR (mm) 37.5 ±25.3 36.9 ± 18.4 -14.2 (-22  to -6.3) — 22 ( — 31 to -13.4)
Haemoglobin (mmol/1) 7.2 ± 1.0 7.3 + 0.8 0.37 (0 to 0.7) 0.14 (-0 .2  to 0.4)
M C V  (fl) 86.8 ±8.7 89.8 ±6.6 0.08 (-3.1 to 3.2) 3.09 (1.5 to 4.7) <0.05
Platelets (x  109/l) 361 + 123 300 ± 45 -32 (-85  to 21) -35 ( — 54 to -16)
C R P  (mg/1) 63 + 50 77 ±67 -40 (- 60  to -20) -53 ( — 91 to -16)
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DAS, disease activity score; M TX, methotrexate; SASP, sulphasalazine; D M A R D s , disease-modifying 
ESR, erythrocyte sedimentation rate; MCV, mean corpuscular volume; CRP, C-reactive protein.
P values refer to significant differences between therapy groups.
*Except in the number of painful joints (P<0 .05 ) no significant difference was observed at baseline.
anti-rheumatic drues; VAS, visual analogue scale; RF, rheumatoid factor;
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distribution-free test for curve analysis [40]. Spear­
man’s rank correlation coefficient was used to elevate 
correlations between variables at study entry, and 
between changes in variables after 24 weeks. A two- 
sided P value of 0.05 was considered to be significant. 
The clinical trial was an open study [35], but cytokine 
measurements were performed in a modified single­
blind fashion.
RESULTS
Clinical results
No significant differences in pretreatment character­
istics were observed between both treatment groups 
except for the number of painful joints which was 
higher in the group treated with combination therapy 
(Table I). After 24 weeks of treatment, improvement 
was observed in both treatment groups. However, the 
combination therapy proved to be superior to MTX 
alone as reflected by the more pronounced changes in 
clinical variables including the Ritchie Articular Index, 
DAS, number of swollen and painful joints, general 
well-being, pain score, grip strength (Table I) and the 
number of patients where the MTX dose was increased 
after 16 weeks because of lack of improvement (/? = 8, 
all but one in the MTX group). Toxicities occurred 
with similar frequency in both treatment groups and 
were observed in seven patients treated with MTX 
alone (gastrointestinal n = 5, increase in transaminases 
n = 2, headache n = 1, stomatitis n = 1) and in six 
patients treated with MTX + SASP (gastrointestinal 
n = 2, increase in transaminases n = 5). One patient in 
the combination group dropped out at week 4 because
of the development of an ‘overlap syndrome’ with 
leucopenia, lung abnormalities, skin lesions and anti-ds 
DNA antibodies. The results of this small open study 
suggest that the combination MTX -f- SASP is clinically 
superior and not more toxic than MTX alone [35]. 
This is currently being evaluated in large double-blind 
trials comparing MTX + SASP versus the individual 
components.
Baseline comparisons in cytokine concentrations
Compared to healthy controls, the circulating con­
centrations of IL-6, soluble TNF and IL-2 receptors 
and IL-1RA and the spontaneous production of 
secreted and cell-associated IL-1/?, TNFa and IL-1RA 
by PBMNC were significantly higher in RA patients 
(Table II). The production of cell-associated cytokines 
after in vitro stimulation was also higher in RA patients 
and this difference was significant for TNFa and 
IL-1RA. In contrast, the concentrations of IL-l/i and 
TNFa in the circulation and the secreted amount of 
IL-1 /?, TNFa and IL-1RA after PBMNC stimulation 
were similar in patients and controls (Table II). No 
differences in pretreatment levels of circulating cyto­
kines or cytokine production by PBMNC were 
observed between treatment groups (data not shown). 
In RA patients, circulating IL-1RA concentrations 
were higher (median 4-fold) than those of IL-l/i and 
the ratio sTNFR to TNFa was 20-30 and 40-70 for 
p55 and p75, respectively. The spontaneous production 
of IL-1RA in vitro exceeded that of IL-1 /? by 10-20- 
fold in the secreted fraction and 3-6-fold in the 
cell-associated fraction, respectively. In contrast, the
TABLE II
Circulating cytokines and cytokine production by PBM N C in healthy controls and RA patients at baseline. Median and (25, 75 percentile)
Variable Controls (n = 30) Patients (n =  26) P
Circulating concentrations
IL-I/i (pg/ml) 65 (ND-90) 77.5 (70-85) NS
TNFa (pg/ml) 105 (85-115) 92.5 (75-105) NS
IL-6 (U/ml) 1.6 (1.2-2.2) 29.4 (11.5-38.9) <0.001
p55 (pg/ml) 950 (630-1100) 2110 (1730-2700) <0.001
p75 (pg/ml) 3035 (2710-3290) 4785 (3720-7150) <0.001
sIL-2R (pg/ml) 1825 (1300-2838) 4625 (3150-7200) <0.001
IL-1RA (pg/ml) 220 (205-285) 312 (230-520) 0.005
Production by PBMNC : 
Secreted without stimulation
IL-l/y (pg/ml) 100 (65-165) 375 (155-1940) <0.001
TNFa (pg/ml) 72.5 (ND-150) 152.5 (65-565) 0.01
IL-1RA (pg/ml) 2880 (2420-4070) 5305 (2480-7200) 0.02
Cell-associated without stimulation
\L-[ß (pg/ml) 257 (185-510) 743 (485-1840) <0.001
TNFa (pg/ml) N D N D 72.5 (35-135) <0.001
IL-1RA (pg/ml) 1690 (1250-2200) 4810 (1270-6690) 0.005
Secreted after stimulation
IL-1 /? (pg/ml) 10 650 (6970-14 100) 10 500 (4080-15 400) NS
TNFa (pg/ml) 2535 (1930-3590) 3445 (1570-5500) NS
IL-RA (pg/ml) 7745 (5360-10 600) 8990 (5760-13 200) NS•
Cell-associated a fter stimulation
IL-l/i (pg/ml) 4985 (3080-6470) 7690 (3520-13 200) NS
TNFa (pg/ml) 195 (120-230) 290 (185-390) 0.02
IL-1RA (pg/ml) 4860 (2750-6780) 7895 (3430-14 000) 0.02
PBM NC, peripheral blood mononuclear cells; N D , not detectable, NS, not significant.
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median concentrations of IL-IRA and IL-l/i produced 
after PBMNC stimulation were similar (Table II).
Effects o f treatment in cytokine concentrations
Significant decreases in IL-6 and sIL-2R (Fig. 1A 
and B) occurred in both treatment groups. The baseline 
concentrations of sTNFR in the circulation (Fig. 1C 
and D) and the production of cell-associated IL-1 /? and 
IL-1RA (Fig. 2A and B) after PBMNC stimulation 
tended to be higher (not significant) in patients treated
9
with MTX + SASP, and significant decreases during 
follow-up were only observed in this treatment group. 
The secreted amount of IL-l/i after PBMNC stimu­
lation decreased after 4 weeks, especially in the 
group treated with MTX alone, however, the median 
values at week 24 were not significantly different from 
baseline (Fig. 2C). Neither the circulating levels of 
IL-1RA (Fig. IE), IL-1/?, and TNFa nor the spon­
taneous production or the secretion of these cytokines 
after PBMNC stimulation (data not shown) showed
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Fig. 1.— Circulating concentrations of interleukin-6 (A), soluble receptors for interleukin-2 (B), soluble tumour necrosis factor receptors 
(C, D) and interleukin-1 receptor antagonist (E) in patients treated with methotrexate (MTX) alone (dotted boxes) and with the combination 
of M TX  and sulphasalazine (hatched boxes). Cytokine concentrations on the v-axis, time in weeks on the A'-axis. Horizontal line shows the 
median. Vertical line represents the range. Box shows the p75 and p25 values. A ,  value above the >’-axis range and *P < 0.05 (closed testing)
[39].
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significant changes during the study. Longitudinal 
comparison of circulating cytokines and cytokine pro­
duction, corrected for pretreatment values, did not 
show significant differences between treatment groups.
Interrelationships between cytokines and other para­
meters
sTNFR and sIL-2R showed positive correlations 
with the DAS, number of swollen joints, C-reactive 
protein (CRP) and IL-6 and negative correlations with 
haemoglobin concentrations (Table III). IL-6 measure­
ments also correlated with baseline CRP (/* = 0.49, 
P < 0.05) and ESR (r = 0.58, P < 0.005). The pro­
duction of IL-1 /?, TNFa and IL-1RA by PBMNC 
showed significant interrelationships but no correlation 
with circulating cytokine levels and clinical or labora­
tory measurements of disease activity (data not shown).
DISCUSSION
In the present study circulating cytokines 
(IL-l/i, TNFa, IL-6, IL-1RA), soluble receptors (sIL- 
2R and sTNFR) and the production of IL-l/i, TNFa 
and IL-1RA by PBMNC were longitudinally assessed 
in patients with active RA enrolled in a randomized 
open trial of MTX combined with SASP vs MTX 
alone [35]. Potential different effects of combination 
(MTX-f SASP) and single drug (MTX) therapy on 
the cytokine network could be relevant since: (a) 
MTX + SASP seemed superior and not more toxic 
than MTX alone in the clinical study [35] and (b) 
previous reports had suggested that MTX and SASP 
may differ in their modulation of circulating cytokines 
and cytokine production [24-33].
Several of the parameters studied showed important 
changes during therapy and there were some differ­
ences between both therapy groups. Significant 
decreases in the circulating sTNFR levels and in the 
production of cell-associated IL-l/i and IL-1RA after 
stimulation were only observed in patients treated with 
MTX + SASP but not in the MTX group (Figs 1 and 
2). This difference may reflect the fact that baseline 
levels of these parameters were higher (not significant) 
in the group treated with MTX -f SASP, and that 
decreases are more likely to occur in this case. On the 
other hand, it might result from an additional or 
specific effect of SASP on the release of TNF receptors 
and on the production of IL-1 and its antagonist. Early 
decreases in IL-6 and sIL-2R concentrations occurred 
in both therapy groups, being also more marked in the 
group with higher pretreatment levels whereas the 
levels of IL-1/?, TNFa and IL-1RA in the circulation 
remained unchanged.
We have previously demonstrated that MTX therapy 
does not alter TNFa but reduces IL-6 and sIL-2R 
concentrations [19] and this has been corroborated by 
other authors [20,41]. However, our findings in 
patients receiving combination therapy do not support 
the claim that SASP reduces circulating levels of IL-l/i 
and TNFa as reported by Danis et al. [32].
In patients with active RA, we have observed 
reductions in the secretion of IL-l/i by stimulated
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Fig. 2.— In vitro production of cell-associated interleukin-1 (i (IL-l /i) 
(A), cell-associated interleukin-1 receptor antagonist (B) and secreted 
IL-l/y (C) after peripheral blood mononuclear cell stimulation in 
patients treated with methotrexate (M TX) alone (dotted boxes) and 
with the combination of M TX and sulphasalazine (hatched boxes). 
Cytokine concentrations on the v-axis, time in weeks on the a*-axis. 
Horizontal line shows the median. Vertical line represents the range. 
Box shows the p75 and p25 values. A , value above the v-axis range 
and *P < 0.05 (closed testing) [39].
PBMNC after the first MTX dose [31]. Similar effects 
were observed in the present study after 4 weeks of 
MTX therapy. This effect was not progressive over the 
time, and also not observed in the group treated with 
combination therapy which had lower IL-l/i secretion 
at baseline. Therefore, although MTX may decrease 
IL-l/i secretion in some patients in the short term, it is
BARRERA ET AL:. METHOTREXATE ALONE OR WITH SULPHASALAZINE IN RA 753
TABLE III
Correlation between circulating concentrations of sTNFR and sIL-2R and several cytokines and clinical and laboratory parameters. Spearman
correlation coefficient between absolute values at entry and between changes vs baseline after 24 weeks
p55 sIL-2R p75
Entry 24 weeks Entry 24 weeks Entry 24 weeks
DAS 0.61 ** 0.66*** 0.48* 0.45* 0.61** 0.43*
Swollen joints 0.67*** 0.64** 0.56** 0.56** 0.59** 0.44*
CRP 0.45* 0.59** 0.35 0.52*
Haemoglobin -0.46* -0.44* -0.40* -0.47*
p75 0.81*** 0.68*** 0.67*** 0.68***
sIL-2R 0.65*** 0.63**
IL-6 0.53** 0.52*
IL-1 RA 0.61** 0.63**
DAS, disease activity score; CRP, C-reactive protein.
***P <0.001, **P < 0.005, *P <0.05.
unlikely that this explains the sustained therapeutic 
effect of this drug. Our results show that, compared to 
healthy controls, RA patients have significantly higher: 
(a) circulating levels of IL-6, sIL-2R, sTNFR and 
IL-1RA, (b) spontaneous production of secreted and 
cell-associated IL-l/i, TNFa and IL-1RA, and (c) 
stimulated production of cell-associated TNFa, IL- 
1 RA and IL-1 /i (not significant) by PBMNC (Table II). 
Elevated concentrations of IL-6 [42,43], sIL-2R 
[18-20] and sTNFR [19,21] have been previously re­
ported in RA. These parameters are interrelated and 
show positive correlations with some measures of 
disease activity (Table III). Therefore, a decrease in 
their circulating levels during therapy probably reflects 
clinical improvement. Although it is not likely that 
these parameters will supersede current disease activity 
assessments, they may have some value as disease 
activity markers. In contrast, the concentrations of 
IL-1/? [44, 45] and TNFa in plasma are low and similar 
in RA patients and healthy controls. The increased 
serum TNFa concentrations reported in some studies 
[19,42,46] might have been due to production of 
TNFa in the blood sample during clotting or to 
endotoxin contamination [47, 48]. Our results corrob­
orate former findings of an increased spontaneous 
production [49-52] and a normal IL-l/i secretion after 
LPS stimulation [49] in RA. With regard to the pro­
duction of TNFa in RA, previous reports have yielded 
contradictory results [51,53]. The higher spontaneous 
in vitro production of cytokines in RA may well reflect 
an activation of PBMNC in vivo.
When the ratios of endogenous antagonists (IL-1 RA 
and sTNFR) to agonists (IL-1 and TNF, respectively) 
were analysed, a moderate excess of the antagonists 
was observed in the circulation. The spontaneous pro­
duction of IL-1RA by PBMNC was also somewhat 
higher than the IL-1/? production but this was not the 
case after LPS stimulation. Furthermore, we have 
previously shown that PBMNC from RA patients 
do not release sTNFR either spontaneously or after 
stimulation [31]. Since 10-500- and 30-300-fold higher 
levels of IL-1 RA [16, 17] and sTNFR [54], respectively 
are required for 50% suppression of IL-1 and TNF 
bioactivity, the concentrations of antagonists measured
in this study may not be adequate to block completely 
the effects of IL-1 and TNF. An imbalance between 
IL-1 and IL-1RA has already been suggested to play a 
role in the pathogenesis of RA [17,55] and Lyme 
arthritis [56] and this might also be the case for TNFa 
and its soluble receptors. This hypothesis, sustained by 
the promising results of clinical studies with IL-1RA 
[13] and anti-TNFa monoclonal antibodies [14] in RA, 
encourages further research in the field of anticytokine 
strategies.
Taken together, our results show that circulating 
concentrations of IL-6, sIL-2R, sTNFR and IL-1RA, 
the spontaneous production of IL-l/i, TNFa and IL- 
1 RA and the cell-associated production of these cytoki­
nes after PBMNC stimulation are elevated in patients 
with active RA. In this open study, the combination 
MTX + SASP seemed clinically superior to MTX 
alone. Reductions of circulating IL-6 and sIL-2R levels 
were observed in both treatment groups, whereas 
decreases in sTNFR concentrations and the in vitro 
production of cell-associated IL-l/i and IL-1RA after 
stimulation occurred only with the combination 
therapy. Whether this relates to the better clinical 
effect in this patient group or is a specific effect of 
SASP remains to be investigated. Furthermore, the 
circulating levels and production of endogenous antag­
onists for IL-1 and TNF in RA may not be sufficient 
to suppress the activity of these pro-inflammatory 
cytokines.
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